Astria Therapeutics (NASDAQ:ATXS) Given Buy Rating at HC Wainwright

Astria Therapeutics (NASDAQ:ATXS)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a research note issued on Thursday,Benzinga reports. They presently have a $16.00 price objective on the biotechnology company’s stock. HC Wainwright’s price objective indicates a potential upside of 111.64% from the stock’s current price.

Separately, Oppenheimer boosted their target price on Astria Therapeutics from $26.00 to $28.00 and gave the company an “outperform” rating in a report on Thursday, November 14th. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $25.60.

Astria Therapeutics Price Performance

Shares of NASDAQ:ATXS traded up $0.06 during trading on Thursday, reaching $7.56. The company had a trading volume of 108,217 shares, compared to its average volume of 299,841. The firm has a market capitalization of $426.61 million, a price-to-earnings ratio of -3.62 and a beta of 0.70. The stock’s fifty day moving average price is $9.21 and its 200 day moving average price is $10.60. Astria Therapeutics has a fifty-two week low of $7.16 and a fifty-two week high of $16.90.

Institutional Trading of Astria Therapeutics

A number of institutional investors have recently modified their holdings of the business. FMR LLC boosted its stake in shares of Astria Therapeutics by 29.2% in the third quarter. FMR LLC now owns 7,822,275 shares of the biotechnology company’s stock valued at $86,123,000 after buying an additional 1,767,714 shares in the last quarter. RA Capital Management L.P. boosted its position in Astria Therapeutics by 1.2% during the third quarter. RA Capital Management L.P. now owns 5,105,213 shares of the biotechnology company’s stock worth $56,208,000 after purchasing an additional 61,457 shares in the last quarter. Vestal Point Capital LP boosted its position in Astria Therapeutics by 23.1% during the third quarter. Vestal Point Capital LP now owns 4,000,000 shares of the biotechnology company’s stock worth $44,040,000 after purchasing an additional 750,000 shares in the last quarter. Millennium Management LLC boosted its position in Astria Therapeutics by 13.5% during the second quarter. Millennium Management LLC now owns 1,842,063 shares of the biotechnology company’s stock worth $16,763,000 after purchasing an additional 218,518 shares in the last quarter. Finally, Nantahala Capital Management LLC purchased a new stake in Astria Therapeutics during the second quarter worth $6,142,000. 98.98% of the stock is currently owned by hedge funds and other institutional investors.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.